Mechanisms of therapy-related carcinogenesis

被引:211
作者
Allan, JM [1 ]
Lois, BT
机构
[1] Univ York, Dept Biol, Epidemiol & Genet Unit, York YO10 5YW, N Yorkshire, England
[2] NCI, Div Canc Epidemiol & Genet, NIH, Dept Hlth & Human Serv, Bethesda, MD 20892 USA
关键词
D O I
10.1038/nrc1749
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Therapy-related cancers, defined as second primary cancers that arise as a consequence of chemotherapy and/or radiotherapy, are unusual in that they have a well-defined aetiology. Knowledge of the specific nature of the initiating exposure and exactly when it occurred has made it easier to identify crucial genetic events and to model these in vitro and in vivo. As such, the study of therapy-related cancers has led to the elucidation of discrete mechanisms of carcinogenesis, including DNA double-strand-break-induced gene translocation and genomic instability conferred by loss of DNA repair. Unsurprisingly, some of these mechanisms seem to operate in the development of sporadic cancers.
引用
收藏
页码:943 / 955
页数:13
相关论文
共 141 条
[31]   An MII-AF9 fusion gene made by homologous recombination causes acute leukemia in chimeric mice: A method to create fusion oncogenes [J].
Corral, J ;
Lavenir, I ;
Impey, H ;
Warren, AJ ;
Forster, A ;
Larson, TA ;
Bell, S ;
McKenzie, ANJ ;
King, G ;
Rabbitts, TH .
CELL, 1996, 85 (06) :853-861
[32]  
de Wind N, 1998, CANCER RES, V58, P248
[33]   Mouse embryonic stem cells carrying one or two defective Msh2 alleles respond abnormally to oxidative stress inflicted by low-level radiation [J].
DeWeese, TL ;
Shipman, JM ;
Larrier, NA ;
Buckley, NM ;
Kidd, LR ;
Groopman, JD ;
Cutler, RG ;
te Tiele, H ;
Nelson, WG .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (20) :11915-11920
[34]   INACTIVATION OF THE MOUSE MSH2 GENE RESULTS IN MISMATCH REPAIR DEFICIENCY, METHYLATION TOLERANCE, HYPERRECOMBINATION, AND PREDISPOSITION TO CANCER [J].
DEWIND, N ;
DEKKER, M ;
BERNS, A ;
RADMAN, M ;
RIELE, HT .
CELL, 1995, 82 (02) :321-330
[35]   The MII-AF9 gene fusion in mice controls myeloproliferation and specifies acute myeloid leukaemogenesis [J].
Dobson, CL ;
Warren, AJ ;
Pannell, R ;
Forster, A ;
Lavenir, I ;
Corral, J ;
Smith, AJH ;
Rabbitts, TH .
EMBO JOURNAL, 1999, 18 (13) :3564-3574
[36]  
DOMER PH, 1995, LEUKEMIA, V9, P1305
[37]   Second malignant neoplasms among long-term survivors of Hodgkin's disease: A population-based evaluation over 25 years [J].
Dores, GM ;
Metayer, C ;
Curtis, RE ;
Lynch, CF ;
Clarke, EA ;
Glimelius, B ;
Storm, H ;
Pukkala, E ;
van Leeuwen, FE ;
Holowaty, EJ ;
Andersson, M ;
Wiklund, T ;
Joensuu, T ;
van't Veer, MB ;
Stovall, M ;
Gospodarowicz, M ;
Travis, LB .
JOURNAL OF CLINICAL ONCOLOGY, 2002, 20 (16) :3484-3494
[38]  
DORES GM, 2005, J CLIN ONCOL S, V23, P6511
[39]   Cisplatin and adriamycin resistance are associated with MutL alpha and mismatch repair deficiency in an ovarian tumor cell line [J].
Drummond, JT ;
Anthoney, A ;
Brown, R ;
Modrich, P .
JOURNAL OF BIOLOGICAL CHEMISTRY, 1996, 271 (33) :19645-19648
[40]   Human MutS alpha recognizes damaged DNA base pairs containing O-6-methylguanine, O-4-methylthymine, or the cisplatin-d(GpG) adduct [J].
Duckett, DR ;
Drummond, JT ;
Murchie, AIH ;
Reardon, JT ;
Sancar, A ;
Lilley, DM ;
Modrich, P .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1996, 93 (13) :6443-6447